Recruiting
Phase 1

MVB-101

Sponsor:

MultiValent Biotherapies, Inc.

Code:

NCT07944508

Conditions

Localized Prostate Adenocarcinoma

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MVB-101

Study Details

Brief summary:

This Phase 1, open-label, non-randomized, multicenter study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MVB-101 administered by direct intraprostatic injection in adults with previously untreated localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy. Participants will receive MVB-101 once weekly for 4 weeks. Part A will use an i3+3 dose-escalation design to evaluate dose levels of 1, 2, 4, and 8 mg and determine the maximum tolerated dose and recommended Phase 2 dose. Part B will use a Simon two-stage dose-expansion design at one or more selected dose levels to further characterize safety and preliminary efficacy. Participants will undergo safety, pharmacokinetic, multiparametric magnetic resonance imaging, pathological, prostate-specific antigen, and patient-reported outcome assessments.

Conditions

Localized Prostate Adenocarcinoma

Study ID

NCT07944508

Start date

Aug 14, 2026

Status verified date

Nov, 2026

Completion date

Mar, 2028

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Signed informed consent form.
  • Understands the obligation and is capable of attending all follow-up visits.
  • Documented, previously untreated, localized adenocarcinoma of the prostate confirmed by multiparametric MRI and prostate biopsy within 3 months before the first dose.
  • Scheduled for radical prostatectomy approximately 12 weeks after the first dose of MVB-101.
  • Gleason Grade Group 1 with at least one high-risk feature, or Grade Group 2, 3, or 4. High-risk features for Grade Group 1 are PSA density >0.2 ng/mL/cc, PI-RADS 4 or 5, lesion >1.0 cm, lesion volume >0.4 cc, or risk of extraprostatic extension evidenced by capsular abutment or bulge.
  • Prostate-specific antigen 20 ng/mL or less.
  • Eastern Cooperative Oncology Group performance status 0 or 1.
  • Adequate bone marrow and organ function.
  • Sexually active participants agree to use barrier protection during treatment and for 1 month after the last MVB-101 dose.

Exclusion Criteria:

  • Any prior treatment for prostate cancer, except prior active surveillance is permitted.
  • More than 10 mg/day of systemic steroids within 28 days before signing informed consent.
  • Prior exposure to auristatin, an auristatin derivative, or a similar molecule.
  • Prior or concurrent malignancy whose natural history or treatment could interfere with or affect MVB-101 safety or efficacy assessments.
  • Prostatic calcifications.
  • Inability to undergo MRI scanning for any reason, including claustrophobia or implanted devices.
  • Major surgery within 4 weeks before first dose or planned during the study, other than prostatectomy.
  • Toxicity attributed to prior anticancer therapy, other than alopecia and fatigue, not resolved to Grade 1 or baseline before first dose.
  • Poorly controlled concurrent disease, including diabetes or hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg).
  • Within 12 months before enrollment: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, or NYHA class III or IV congestive heart failure.
  • History of clinically significant lung disease, including interstitial pneumonia, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis, or suspected disease on screening imaging.
  • Active bleeding disorder or other history of Grade 3 or higher hemorrhage within 4 weeks before first dose.
  • Need for oral vitamin K antagonist anticoagulant therapy. Low-dose anticoagulants to maintain central venous access patency or prevent deep venous thrombosis and therapeutic low-molecular-weight heparin are permitted.
  • Deep vein thrombosis or pulmonary embolism within 6 months before first dose.
  • Active infection requiring intravenous antibiotics within 1 week before first dose.
  • Uncontrolled HIV, known AIDS, chronic hepatitis B, occult hepatitis B, or hepatitis C.
  • Current or anticipated need for a strong CYP3A4 inhibitor or inducer. Prior use requires a washout of 21 days or 5 half-lives, whichever is longer, before first dose.

Study Design

Enrollment

60 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Part A: MVB-101 1 mg

MVB-101 1 mg by intraprostatic injection once weekly for 4 weeks.

experimental: Part A: MVB-101 2 mg

MVB-101 2 mg by intraprostatic injection once weekly for 4 weeks.

experimental: Part A: MVB-101 4 mg

MVB-101 4 mg by intraprostatic injection once weekly for 4 weeks.

experimental: Part A: MVB-101 8 mg

MVB-101 8 mg by intraprostatic injection once weekly for 4 weeks.

experimental: Part B: MVB-101 Dose Expansion

MVB-101 at one or more selected dose levels by intraprostatic injection once weekly for 4 weeks. Other schedules may also be explored.

Interventions

MVB-101

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Primary outcome measure

  • Treatment-emergent adverse events [ Time Frame: From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90) ]
  • Dose-limiting toxicities [ Time Frame: Day 1 through Day 29 ]
  • Maximum tolerated dose [ Time Frame: Through completion of Part A dose escalation, up to 12 months ]
  • Recommended Phase 2 dose [ Time Frame: Through completion of dose escalation and applicable dose-expansion, up to 18 months ]

Central Contacts and Locations

Central contacts

Locations

Urology Centers of Alabama

Recruiting

Homewood, Alabama, United States, 35209

Contacts

Urology San Antonio

Recruiting

San Antonio, Texas, United States, 78229

Contacts

More Information

Sponsor

MultiValent Biotherapies, Inc.

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • MVB-101
  • intraprostatic injection
  • prostate-specific membrane antigen
  • PSMA
  • folate receptor alpha
  • neoadjuvant treatment
  • prostatectomy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by MultiValent Biotherapies, Inc. on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.